Merus (MRUS) Financial Analysis & Valuation | Quarter Chart
Merus (MRUS)
MRUSPrice: $90
Fair Value: 🔒
🔒score
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients wit... more
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bi... more
Description
Shares
| Market Cap | $6.83B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | NL | CEO | Jan van de Winkel |
| IPO Date | 2016-05-19 | CAGR | 0.46% |
| Employees | 260 | Website | www.merus.nl |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
MRUS chart loading...
Fundamentals
Technicals
| Enterprise Value | $6.82B | P/E Ratio | -17.05 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 128.91 | P/B Ratio | 10.29 |
| P/CF Ratio | -21.47 | P/FCF Ratio | -21.47 |
| EPS | $-5.28 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 61.31% | Gross Margin | -2.07% |
| Operating Margin | -6.53% | Profit Margin | -6.59% |
| ROE | -0.51% | ROA | -0.45% |
| ROCE | -0.5% | Current Ratio | 7.97 |
| Quick Ratio | 7.97 | Cash Ratio | 4.23 |
| Debt/Equity | 0.02 | Interest Coverage | — |
| Altman Z Score | 34.55 | Piotroski Score | 3 |